Clinical trial NCT04866836 - References

Cholangiocarcinoma — A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Citation(s)

•   Liu ZL, Liu X, Peng H, Peng ZW, Long JT, Tang D, Peng S, Bao Y, Kuang M
  Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report. Front Med (Lausanne). 2020 Aug 28;7:368. doi: 10.3389/fmed.2020.00368. eCollection 2020.
•   Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ
  Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018 Feb;15(2):95-111. doi: 10.1038/nrclinonc.2017.157. Epub 2017 Oct 10. Review.
•   Saeed A, Park R, Al-Jumayli M, Al-Rajabi R, Sun W
  Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma. Clin Colorectal Cancer. 2019 Jun;18(2):81-90. doi: 10.1016/j.clcc.2019.02.005. Epub 2019 Feb 27. Review.
•   Sui M, Li Y, Wang H, Luo Y, Wan T, Wang X, Hu B, Cheng Y, Lv X, Xin X, Xu Q, Wang G, Lu S
  Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade. J Immunother Cancer. 2019 May 7;7(1):125. doi: 10.1186/s40425-019-0596-y.

A Single-arm, Open, Exploratory Clinical Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Details for clinical trial NCT04866836